Fig. 3: MTHFD2 knockdown inhibits MM malignancy in vivo. | Cell Death Discovery

Fig. 3: MTHFD2 knockdown inhibits MM malignancy in vivo.

From: Targeting MTHFD2 alters metabolic homeostasis and synergizes with bortezomib to inhibit multiple myeloma

Fig. 3

A NCI-H929 and OPM2 cells stably infected with shNC, shMTHFD2#1 or shMTHFD2#2 lentivirus were subcutaneously injected into NOG mice to establish MM xenograft mouse models (n = 6 per group). Tumors from mice described above were dissected and photographed on day 21. B, C Tumor volume and weight were then assessed. These mouse experiments were repeated once. D Paraffin-embedded tumor sections of shNC, shMTHFD2#1 and shMTHFD2#2 groups were stained with hematoxylin and eosin (HE), Ki67 and cleaved caspase-3 antibodies (scale bar 100 μm). E Western blot assay was used to confirm the MTHFD2 knockdown efficiency of tumors from shNC, shMTHFD2#1 and shMTHFD2#2 groups. The data are presented as mean ± SD. Student’s t test was used to compare the differences between two groups (**P < 0.01, ***P < 0.001, ****P < 0.0001).

Back to article page